Real|world first|line treatment of patients with BRAFV600E|mutant ...

Real-world first-line treatment of patients with BRAF V600E -mutant ...

Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022 Dec;7 ...

Real-world first-line treatment of patients with BRAFV600E-mutant ...

Surprisingly, 6.8% of BRAFV600E-mutant patients in CAPSTAN CRC had a concomitant RAS mutation, although this is rare and these mutations are generally ...

Treatment of patients with BRAF V600E -mutated metastatic ...

Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC.

P-49 A study of first-line treatments for patients with BRAFV600E ...

The BRAF V600E mutation is associated with poor prognosis in patients with metastatic colorectal cancer (MCRC), and findings from clinical trials have ...

(PDF) Real-world first-line treatment of patients with BRAFV600E ...

[9][10][11] Furthermore, almost 90% of CRC patients with BRAF V600E mutation do not harbour Rat Sarcoma Protein (RAS) gene mutations, as both ...

Real‐world treatment and outcomes of patients with metastatic ...

Of the remaining 246 BRAF mutant mCRCs, BRAF V600E mutation accounted for 91.5% (n = 235) of all cases. The BRAF non-V600E mutations included 6 ...

438P First line treatment patterns in BRAFV600E-mutant metastatic ...

8-12% of mCRC patients harbour a BRAFV600E mutation (BRAFMT), which confers a poor prognosis. In the first-line setting, there is no specific treatment for ...

Survival comparison of first-line treatment regimens in patients with ...

Among patients with BRAF mutations, the BRAF V600E mutation is the most common, accounting for ~ 80% [16]. At present, according to the 2021 ...

Real-World Treatment Patterns and Effectiveness of Targeted and ...

... real-world patients with BRAF mutations ... Dual-targeted BRAF/MEK inhibition is currently the recommended first-line treatment for BRAF-V600E– ...

Treatment of metastatic colorectal cancer with BRAF V600E mutation

... patients with BRAF mutations [10]. However, the optimal first-line treatment for BRAF V600E-mutated mCRC patients is still controversial. In the TRIBE study ...

European expert panel consensus on the clinical management of ...

10. Martinelli, E. ... Real-world first-line treatment of patients with BRAF(V600E)-mutant metastatic colorectal cancer: ...

DISEASE CHARACTERISTICS AND REAL-WORLD TREATMENT ...

In just over half of the patients with BRAFV600E-mutant. mCRC, primary tumor was located on the right side of the colon, which is in line with ...

BRAF V600E-mutation leads a true change both in diagnosis and ...

They advised to radiologically monitor BRAFV600E-mutant mCRC patients more frequently than those without BRAFV600E mutations (at least every 2 ...

mutant metastatic NSCLC: disease overview and treatment landscape

BRAFV600E is the most prevalent class I mutation and accounts for ~30–50% of all BRAF mutations in NSCLC. Class I mutant proteins have a high ...

Real‐world treatment and outcomes of patients with metastatic ...

Background. BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs). Patients with BRAF mutant mCRC exhibit a specific ...

Real-world occurrence, therapy, and outcome of patients with class ...

Selected class 2 mutations may confer sensitivity to BRAF/MEK inhibitors. This highlights the rationale for a mutation, rather than class- ...

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-V600E mutation in their tumors, which is associated ...

Treating Patients With BRAF V600E Mutation and Advanced RAI ...

EP: 6.Real-World Data on Older Patients With RAI-Refractory DTC ... care in patients with second-line progressive BRAF V600E mutation–positive PTC ...

European expert panel consensus on the clinical management of ...

The BRAF mutation is found in the tumours of 8–12% of patients with mCRC [14]. The clinical management and treatment choices for patients with BRAFV600E-mutant ...

Real-world treatment patterns and overall survival in BRAF-mutant ...

For patients who have tumors with the BRAF V600E mutation, TT with BRAF-MEK inhibitors (combination therapy with dabrafenib and trametinib, vemurafenib and ...